PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24560924-4 2014 Structural analysis of oncogenic M918T and wild-type RET kinase domains reveal a cis-inhibitory mechanism involving tethering contacts between the glycine-rich loop, activation loop, and alphaC-helix. Glycine 147-154 ret proto-oncogene Homo sapiens 53-56 16772843-2 2006 Screening for MEN 2B revealed a polymorphism of the RET proto-oncogene at codon 691 with a glycine to serine conversion. Glycine 91-98 ret proto-oncogene Homo sapiens 14-20 16772843-2 2006 Screening for MEN 2B revealed a polymorphism of the RET proto-oncogene at codon 691 with a glycine to serine conversion. Glycine 91-98 ret proto-oncogene Homo sapiens 52-55 16427628-2 2006 We showed that all RET-PTC-1 mutants in which the C in this motif (C376) was replaced with glycine, lysine, threonine or serine lost their activity in vitro. Glycine 91-98 ret proto-oncogene Homo sapiens 19-22 15184865-4 2004 Substitution of valine 804 with the small amino- acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC(50): 20 nM) than the wild-type kinase. Glycine 54-61 ret proto-oncogene Homo sapiens 74-77 8765374-4 1996 Ten different types of mutations were identified in the MEN 2A/FMTC families (620 Cys-->Arg, 618 Cys-->Ser, Gly, 611 Cys-->Tyr; 634 Cys-->Arg, Tyr, Trp, Phe, Ser, Gly) and all 6 MEN 2B families had a 918 Met-->Thr point mutation. Glycine 114-117 ret proto-oncogene Homo sapiens 56-62 8654369-7 1996 The HSCR972 (Arg972-->Gly) mutation, mapping in the intracytoplasmic region of RET, impaired its tyrosine kinase activity, while two extracellular mutations, HSCR32 (Ser32-->Leu) and HSCR393 (Phe393-->Leu), inhibited the biological activity of RET by impairing the correct maturation of the RET protein and its transport to the cell surface. Glycine 25-28 ret proto-oncogene Homo sapiens 82-85